Correlation between B type natriuretic peptide and metabolic risk factors

Archives of Medical Science

Volumn 12, Issue 2, 2016, Pages 334-340

  Zhu, Wen Hua ^a   Chen, Li Ying ^a   Dai, Hong Lei ^a   Chen, Jian Hua ^a   Chen, Yan ^a   Fang, Li Zheng ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

B type natriuretic peptide; Correlation; Metabolic risk factors

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; METABOLIC RISK; QUALITY CONTROL; RISK; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84963719539     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.57001     Document Type: Article

References (28)

1. Piotrowski G, Gawor R, Banach M, Piotrowska A, Rysz J, Gawor Z. High sensitivity C-reactive protein, NT-proBNP and hemodynamic left ventricular function in acute coronary syndrome without ST segment elevation-a preliminary report. Med Sci Monit 2010; 16: CR313-7.
2. Gluba A, Bielecka-Dabrowa A, Mikhailidis D P, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens 2012; 30: 1681-9.
3. Hu DY, Yang ZH. Clinical application and progress in B-type natriuretic peptide testing. Beijing Science and Technology Press, Beijing 2006; 66-7.
4. Piechota M, Banach M, Jacon A, Rysz J. Natriuretic pep-tides in cardiovascular diseases. Cell Mol Biol Lett 2008; 13: 155-81.
5. Zaki ME, El-Bassyouni HT, El-Gammal M, Kamal S. Indicators of the metabolic syndrome in obese adolescents. Arch Med Sci 2015; 11: 92-8.
6. Gundogan K, Bayram F, Gedik V, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci 2013; 9: 243-53.
7. Weng GL. Prognostic value of terminal natriuretic pep-tide and C reactive protein in acute coronary artery syndrome patients. Prevent Treatment Cerebral Vasc Dis 2011; 11: 277-9.
8. Song XX. A consensus defnition of metabolic syndrome reached by International Diabetes Federation. Chin J Diabetes 2005; 13: 178-80.
9. Sui H, Liu C. Relationship between brain natriuretic pep-tide and endocrine diseases. Int J Endocrinol Metabol 2006; 26: 181-3.
10. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular event and death. N Engl J Med 2004; 350: 655-63.
11. Wang W, Zhao D, Liu J, et al. Serum total cholesterol and 10-year cardiovascular risk in a Chinese cohort aged 35-64 years. Chin J Cardiol 2006; 2: 169-73.
12. Bao Y, Shang X, Zhou L, Hu R, Li Y, Ding W. Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci 2011; 7: 247-56.
13. Li D, Zhou JZ. Brain natriuretic peptide and current clinical applications. Adv Cardiovasc Dis 2012; 33: 230-3.
14. Luchner A1, Behrens G, Stritzke J, et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. Eur J Heart Failure 2013; 15: 859-67.
15. Dong HW, Chen H, Zhang XJ. Efects of natriuretic pep-tide level on cardiac function of metabolic syndrome patients. Chin J Gerontol 2009; 11: 1424-6.
16. Wang TJ, Larson MG, Keyes MJ, Levy D. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007; 115: 1345-53.
17. Karasek D, Sinkiewicz W, Błazejewski J. Relationship between B-type natriuretic peptide serum level, echocar-diographic TEI index and the degree ofdiastolic dysfunction in patients with heart failure withpreserved systolic function. Arch Med Sci 2011; 3: 449-56.
18. Zhang MY, Ming J, Zhang NY. Application of serum BNP measurement in diabetic early left cardiac insufciency. Chin J Clin 2011; 5: 6549-53.
19. Lim HS, Patel JV, Nadar S, Hughes EA, Lip GY. Comparison of brain natriuretic peptide and left ventricular diastolic function determined by tissue Doppler in patients with diabetes mellitus, patients with hypertension without diabetes, and in healthy subjects. Am J Cardiol 2005; 95: 905-8.
20. Dawn A, Jeyaseelan S, Morris A, Struthers AD. B-type na-triuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus. Am J Cardiol 2005; 96: 933-4.
21. Olszanecka-Glinianowicz M, Kocelak P, Nylec M, Chudek J, Zahorska-Markiewicz B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci 2012; 8: 214-8.
22. Wei T, Zeng C, Chen L, et al. Bedside test of B-type na-triuretic peptide in the diagnosis of left ventricular dia-stolic dysfunction in hypertensive patients. Eur J Heart Failure 2005; 7: 75-9.
23. Wang TJ, Larson MG, Levy D, et al. Impact of obesity of plasma natriuretic peptide levels. Circulation 2004; 109; 594-600.
24. Sengenes C, Moro C, Galitzky J, Berlan M. Lafontan M. Natrurelic peptides: a new lipolytic pathway in human fat cells. Med Set (Paris) 2005; 21: 61-5.
25. Yu HJ, Jin MJ, Li J, Wang J. Efects of dyslipidemia on plasma brain natriuretic peptide levels of type 2 diabetics. Chin J Diabetes 2011; 19: 358-60.
26. Cicero A F, Derosa G, Mafoli P, Reggi A, Grandi E, Borghi C. Infuence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. Arch Med Sci 2013; 2: 238-42.
27. Hajsadeghi S, Kashani Amin L, Bakhshandeh H, Rohani M, Azizian AR, Jafarian Kerman SR. The diagnostic value of N-terminal pro-brain natriuretic peptide in diferentiat-ing cardioembohc ischemic stroke. J Stroke Cerebrovas Dis 2013; 22: 554-60.
28. Lin FL, Gu KL, Du P, Zhang W, Song TY. Infuential factor of N-terminal pro-B type natriuretic peptide. Hebei Med J 2013; 23: 3618-20.